Business Wire

SYNCORDIS

13.2.2020 13:35:08 CET | Business Wire | Press release

Share
Syncordis is Granted the ‘Support Professionals of the Financial Sector’ Status by Luxembourg Ministry of Finance

Syncordis PSF S.A., a leading Temenos banking software specialist and a subsidiary of Larsen & Toubro Infotech Ltd. (LTI) has been granted ‘Support Professional of the Financial Sector’ (Support PSF, Art 29-3 - OSIP) license by Luxembourg Ministry of Finance. A Professional of the Financial Sector ("PSF") is an entity that is authorized to perform financial sector activities as a regular occupation, in accordance with article 13 of the law. The license strengthens Syncordis’ position as a Temenos Global Services Partner and is valid for an unlimited duration.

The PSF status serves as a guarantee for clients as every PSF Support company must comply with regulatory requirements, be financially stable, and implement a highest level of quality in terms of organization, infrastructure, security and internal controls.

Stéphane Fisch, Managing Director and Head of Managed Services, Syncordis PSF S.A. said, “We have provided onsite production services since 2008, but the growing demand for outsourced production support services and SaaS solutions for Temenos clients called for this strategic move. Syncordis PSF will provide end-to-end managed services to its clients with the highest standards of security, governance, processes and tools. Obtaining the “Support PSF” license marks a major milestone for Syncordis and will give us a competitive edge to add unprecedented value to digital transformation journeys of our clients.”

Sudhir Chaturvedi, President & Executive Board Member, LTI said, “I congratulate Syncordis on this remarkable accomplishment. Syncordis PSF now has full rights to operate primary information systems in the banking sector and can take full responsibility to operate financial institutions’ production environment. This setup enables Syncordis’ clients to fully focus on their core business without worrying about technology and enjoy multiple additional benefits such as locally hosted SaaS solutions, increased transparency and security as well as appropriate management of direct and indirect risks.”

Luxembourgian companies that apply for a PSF license must undergo a lengthy application process with the CSSF. Syncordis started the process in 2018 and submitted 1.500 pages worth of documents over the course of the past two years to comply with and meet all CSSF requirements. Licensed companies are audited yearly and must report to the CSSF on a monthly basis. For more information, go to: http://www.cssf.lu/en/supervision/pfs/support-pfs/

About Syncordis:

Syncordis, a Luxembourg based subsidiary of LTI, delivers high-quality end-to-end implementation and system integration projects with an exclusive focus on Temenos banking software such as Temenos Infinity, Temenos Transact, Temenos Fund Administration, Temenos Infinity Wealth and Temenos DataSource. Syncordis is also the first PSF company that is fully dedicated to Temenos services with capabilities to support all Temenos software suites. With 12 offices across the globe, 500+ experts and complementary services like SaaS and production support, Syncordis enables its international clients to master their digital transformation. This makes Syncordis one of the one-stop service partners for Temenos clients worldwide. For more information please visit www.syncordisconsulting.com

About LTI:

LTI (NSE: LTI) is a global technology consulting and digital solutions Company helping more than 420 clients succeed in a converging world. With operations in 32 countries, we go the extra mile for our clients and accelerate their digital transformation with LTI’s Mosaic platform enabling their mobile, social, analytics, IoT and cloud journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivaled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 30,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees and shareholders. Read more at www.Lntinfotech.com or follow us at @LTI_Global.

Link:

ClickThru

Social Media:

https://www.facebook.com/LarsenToubroInfotech

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release

Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 07:00:00 CET | Press release

Restylane Shaype is now approved in Mexico for temporary augmentation in the chin area and improvement of jawline definition,1 with launch anticipated in H1 2027 Already approved across various markets globally for the chin area,2 this marks Restylane Shaype’s first approval for the jawline worldwide1 The first-and-only shaper on the hyaluronic acid (HA) market, Restylane Shaype features the firmest HA gel available and is powered by proprietary NASHA HD™ technology, developed to build and shape on bone for instant, natural-looking contour and definition3-6 The approval reinforces Galderma's commitment to advancing innovation in the HA category, enabling the company to meet diverse patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expan

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release

The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release

Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye